 The deal was closed the following October to create Evercore ISI Institutional Equities, offering Macro and Fundamental Research, Sales, and Trading execution.In 2014, the firm secured the second highest number of Institutional Investor #1 positions, after J.P. Morgan, and also ranked #5 in total II positions.The same year, Evercore advised AstraZeneca in its defense against Pfizer’s hostile takeover.